Quantcast
Home > Quotes > SCPH

scPharmaceuticals Inc. Common Stock (SCPH) Quote & Summary Data

SCPH 
$2.87
*  
0.03
1.06%
Get SCPH Alerts
*Delayed - data as of Mar. 26, 2019  -  Find a broker to begin trading SCPH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    SCPH After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.85 / $ 3.25
1 Year Target
7
Today's High / Low
$ 2.94 / $ 2.85
Share Volume
18,055
50 Day Avg. Daily Volume
25,641
Previous Close
$ 2.84
52 Week High / Low
$ 15.70 / $ 2.76
Market Cap
53,325,834
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.58
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.21

Intraday Chart

Shares Traded

Share Volume:
18,055
50 Day Avg. Daily Volume:
25,641

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.58

Trading Range

The current last sale of $2.87 is 3.99% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.94 $ 15.70
 Low: $ 2.85 $ 2.76

Company Description (as filed with the SEC)

We are a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous, or IV, delivery. By moving delivery away from the high-cost healthcare settings typically required for IV administration, we believe our technology has the potential to reduce overall healthcare costs and advance the quality and convenience of care. Our lead product candidate, FUROSCIX, consists of our novel, buffered formulation of furosemide delivered subcutaneously via an on-body infusor and is under development for treatment of congestion in patients with worsening heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization.  ... More ...  



Risk Grade

Where does SCPH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.84
Open Date:
Mar. 26, 2019
Close Price:
$ 2.87
Close Date:
Mar. 26, 2019


Consensus Recommendation

Analyst Info